Literature DB >> 25269730

Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.

T McCarthy1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25269730     DOI: 10.1111/jns.12080_4

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


× No keyword cloud information.
  2 in total

1.  EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain.

Authors:  Jan M Keppel Hesselink; Michael E Schatman
Journal:  J Pain Res       Date:  2017-02-20       Impact factor: 3.133

Review 2.  Mirogabalin and emerging therapies for diabetic neuropathy.

Authors:  Saad Javed; Uazman Alam; Rayaz A Malik
Journal:  J Pain Res       Date:  2018-08-22       Impact factor: 3.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.